News

Late-breaking phase 2 data was presented at the 2024 American Academy of Allergy, Asthma and Immunology Annual Meeting.

Platelet-rich plasma (PRP) holds great promise for regenerative hair and skin applications, but trials, standards, and protocols are needed, one review has found.

Biologics to treat psoriasis can cost between $1664 and $79,277 a year in the United States, one study found, and these prices are not commensurate with clinical benefits.

Simlandi (adalimumab-ryvk) joins Pfizer’s Abrilada (adalimumab-afzb) and Boehringer Ingelheim’s Cyltezo (adalimumab-adbm) as an interchangeable Humira biosimilar.

Maternal mental health conditions are associated with the majority of atopic diseases, according to a study.

Keep up with the latest headlines in dermatology from the past week, including the rise of dermatologists offering skin health services for people of color, isotretinoin and its ocular impact, and more.

ICYMI, this week we had news about Masterclasses in Dermatology insights, Alaskapox and skin lesions, improving skin of color representation in dermatology, and more.

Data on pigmentary disorders worldwide and clinical study results were presented at the IMCAS World Congress 2024 meeting.

Miranda Uzoma Ewelukwa, MD, FAAD, reviews how skin of color representation has evolved in dermatology, however, more advocacy is still needed.

Researchers have found Staphylococcus aureus may trigger itchiness in atopic dermatitis, opening the door to new treatment approaches in the future.

Researchers compared the potent depigmenting agent with modified Kligman's formula, considered the gold standard therapy for melasma.

This month's Legal Eagle column highlights the tension between cost control measures and concerns about patient care in the context of health care spending and the increasing prevalence of actinic keratoses

Learn more about dupilumab-induced conjunctivitis rates and misconceptions, the thriving long-term efficacy of dupilumab over 3 years, and unraveling the itch-flare dynamic in abrocitinib treatment.

In a recent study, topical ruxolitinib improved clinical outcomes, itch, and patient quality of life.

Medical therapy should be paired with behavioral therapy to best treat this distressing hair-pulling disorder, researchers claim.

Get a sneak peek ahead of AAD about the LITE study’s patient-centered design, routine care integration, and diverse participant inclusion, offering a cost-effective option in psoriasis treatment.

Findings reveal an increased risk of psoriatic arthritis among female patients with severe skin psoriasis who have nail involvement and require oral systemic therapy for their condition.

The initiative brings awareness and action for people of color to the forefront of the conversation.

Shawn Kwatra, MD, shares insights into neuropathic pruritus’ debilitating effects on patients and how clinicians can use unified nomenclature.

In this week’s Pointers With Portela, the 208SkinDoc reviews a potentially misleading acne vitamin from Clearstem Skincare.

The study found disagreement in perceptions of treatment options and overall disease severity among providers and patients.

The data was recently published in the Journal of the American Academy of Dermatology International.

Researchers utilized studies and papers from the review to define and understand best practices and methods for improving adherence.

This week’s collection of the latest dermatologic studies covers hair matrix cells, comorbidity associations of hidradenitis suppurativa, risk factors of infantile hemangioma, and giant cell collagenomas in a patient with Cowden syndrome.

Barbieri spoke with Dermatology Times to discuss the new guidelines and the recommendations and good practice statements included.

Explore Dermatology Times' coverage of the 2024 Masterclasses in Dermatology conference on topics ranging from artificial intelligence lessons from GI to cardiovascular considerations in psoriasis treatment.

IV antibiotics should play a complementary role in the management of HS as new immunomodulator therapies are developed, researchers concluded.

Officials recently reported the first known fatality from the virus. Here's what health professionals say to watch for.

Researchers sought to expand knowledge of the role of cannabis and its molecular mechanisms in anticancer effects.

Miller, Vice President, Immunodermatology Disease Area Leader, Johnson & Johnson, spoke with Dermatology Times about recently published data supporting JNJ-2113's potential in this indication.